Barr Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of generic and proprietary pharmaceuticals. Its generic product portfolio includes solid oral dosage forms, injectables, and cream/ointment products. The company’s proprietary product portfolio and pipeline is concentrated in the area of female healthcare. As of December 31, 2007, Barr Pharmaceuticals marketed approximately 245 different dosage forms and strengths of approximately 120 different generic pharmaceutical products, including 25 oral contraceptive products in the United States; and 255 different molecules, representing 1,025 generic pharmaceutical products in approximately 2,790 different presentations internationally. It also marketed 26 proprietary pharmaceutical products. These products primarily include SEASONIQUE, an extended-cycle oral contraceptive; PLAN BTM, a dual-label, over-the-counter /Rx emergency contraceptive; ParaGard T 380A, an IUC contraceptive product; Mircette, a 28-day oral contraceptive; and ENJUVIA, a line of hormone therapy products. In addition, Barr Pharmaceuticals has several generic biologics products in various stages of development for the U.S. and European markets, including granulocyte colony stimulating factor, a protein that stimulates the growth of certain white blood cells. It serves drug store chains, supermarket chains, mass merchandisers, wholesalers, distributors, managed care organizations, mail order accounts, group purchasing organizations, and government/military and re-packagers. The company was founded in 1970 and is headquartered in Montvale, New Jersey.